WebApr 21, 2024 · The fundraise comes just eight months after Reify raised a $220 million Series C round, and it brings the startup's valuation to $4.8 billion — more than twice what it was valued in August. WebI’m thrilled to share the latest chapter in the Reify Health story: we’ve closed a $220M Series C financing round from Coatue Management, as well as ICONIQ Capital, Adams Street Partners ...
Reify Health Tracxn
WebApr 21, 2024 · BOSTON, April 21, 2024: Morgan Lewis represented Reify Health, a provider of solutions empowering faster, predictable, and more accessible clinical trials, in the company’s $220 million Series D round. Morgan Lewis partner Carl Valenstein, and associates Benjamin Stein and Bryan Judd advised Reify Health. The firm previously … WebCongrats Ralph Passarella and Bob Proctor on raising $220M Series C for Reify Health. #goodteamswin #alwaysdayone Tarun Upaday on LinkedIn: Reify Health Raises $220 Million to Eliminate Waiting in Clinical Trials expired excedrin safe
Focus Lab® Reify Health
WebApr 21, 2024 · Reify Health Lands $220M Series D Financing. Back to Home. 2024-04-21. Tweet. BOSTON, MA, Reify Health, ... The round was co-led by Altimeter Capital and Coatue, joined by Dragoneer Investment Group and existing investors ICONIQ Growth, Adams Street, and Battery Ventures. This round of funding, ... WebReify Health. Reify Health provides cloud-based software that helps accelerate the development of new, life-saving therapies. The company's system accelerates enrollment … WebApr 21, 2024 · Reify Health, a cloud-based clinical trial software company, raised $220 million in Series D funding. The funding doubles the company’s valuation, putting it at $4.8 billion. The round was co-led by Altimeter Capital and Coatue, with participation from Dragoneer Investment Group, ICONIQ Growth, Adams Street and Battery Ventures. expired epipens effectiveness